3,481 results match your criteria: "University of Orléans and INSERM[Affiliation]"
Intensive Care Med
January 2025
Medical and Infectious Diseases Intensive Care Unit, Bichat Claude Bernard University Hospital, Université Paris Cité, AP-HP, Paris, France.
Intensive Care Med
January 2025
Medical ICU, Assistance Publique-Hôpitaux de Paris, University Hospital Ambroise Paré, Boulogne-Billancourt, France.
Purpose: Prognostic impact of left ventricular diastolic dysfunction (LVDD) in septic shock patients has not been determined using current diagnostic guidelines. We assessed the relation between LVDD during the first 3 days following intensive care unit (ICU) admission for septic shock and Day-28 mortality.
Methods: This prospective, multicenter, observational study enrolled 402 patients (age: 63 ± 13 year; 59% male; SAPS II: 59 ± 20; SOFA: 9.
EuroIntervention
January 2025
Division of Cardiovascular Medicine, State University of New York, Downstate Medical Center, New York, NY, USA.
Hemasphere
January 2025
Department of Laboratory Medicine, Laboratory of Hematology Radboud University Medical Center and Radboud Institute for Molecular Life Sciences Nijmegen The Netherlands.
Eur J Neurol
January 2025
Folkhalsan Research Center, Helsinki, Finland.
Background: myotilinopathy is a very rare inherited muscle disease that belongs to the group of myofibrillar myopathies. These diseases share a common alteration of the sarcomere organization at the level of the Z disk resulting in pathological protein aggregation, autophagic abnormalities, and ultimately muscle degeneration. Most reported cases are due to dominant missense mutations in the MYOT gene, two of which are largely recurrent.
View Article and Find Full Text PDFEur J Anaesthesiol
October 2024
From the Department of Anaesthesiology and Intensive Care, Dijon University Hospital (MN, AO, P-GG, BB), University of Burgundy and Franche-Comté, LNC UMR1231 (MN, AO, P-GG, BB), and INSERM, LNC UMR1231, Lipness Team, Dijon, France (MN, AO, P-GG, BB).
Oncologist
December 2024
Department of Pneumology and Thoracic Oncology, Tenon Hospital, Assistance Publique Hôpitaux de Paris and GRC 4, Theranoscan, Sorbonne Université, Paris, France.
Introduction: The emergence of diverse resistance mechanisms after osimertinib therapy, including on-target epidermal growth factor receptor (EGFR) mutations and off-target alterations, warrants investigation of novel therapeutics to overcome these challenges and improve patient outcomes.
Methods: COMPOSIT was a French, retrospective, multicenter, cohort study of the effectiveness and tolerability of osimertinib in combination with other targeted therapies in patients with advanced EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC) who harbored other oncogenic drivers as primary or acquired resistance mechanisms. Real-world progression-free survival (rwPFS), overall survival (OS), and objective response rate (ORR) were the primary endpoints.
PLOS Digit Health
December 2024
Deep Digital Phenotyping Research Unit. Department of Precision Health, Luxembourg Institute of Health, 1 A-B rue Thomas Edison, L-1445 Strassen, Luxembourg.
The pressing need to reduce undiagnosed type 2 diabetes (T2D) globally calls for innovative screening approaches. This study investigates the potential of using a voice-based algorithm to predict T2D status in adults, as the first step towards developing a non-invasive and scalable screening method. We analyzed pre-specified text recordings from 607 US participants from the Colive Voice study registered on ClinicalTrials.
View Article and Find Full Text PDFDrugs Aging
December 2024
Department of Internal Medicine and Paediatrics, Faculty of Medicine and Health Sciences, University of Ghent, Ghent, Belgium.
Background: Various explicit screening tools, developed mostly in central Europe and the USA, assist clinicians in optimizing medication use for older adults. The Turkish Inappropriate Medication use in oldEr adults (TIME) criteria set, primarily based on the STOPP/START criteria set, is a current explicit tool originally developed for Eastern Europe and subsequently validated for broader use in Central European settings. Reviewed every three months to align with the latest scientific literature, it is one of the most up-to-date tools available.
View Article and Find Full Text PDFIntroduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpopulations with Vp4 portal vein tumor thrombosis (PVTT) and other high-risk prognostic factors are reported.
Methods: IMbrave150 was a global, randomized (2:1), open-label, phase 3 study in systemic treatment-naive patients with unresectable HCC; OS and PFS were co-primary endpoints.
Eur Heart J
December 2024
Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany.
Hypertension
December 2024
Direction des maladies non transmissibles, Santé publique France, Saint-Maurice, France (C.G., A.G., M.J.T., V.O.).
Background: Hypertension is the most common chronic disease and a major modifiable risk factor for cardio-cerebrovascular and renal diseases. This study estimated the national burden of hypertension, defined as systolic blood pressure ≥140 mm Hg, on morbidity and mortality in 2021 in France.
Methods: For all diseases causally associated with hypertension (cardiovascular diseases, chronic kidney diseases, and dementia), the number and proportion of cases attributable to hypertension in adults aged ≥35 years were estimated using population attributable fractions.
United European Gastroenterol J
December 2024
Faculty of Medicine, Department of Biomedicine, Unit of Pharmacology and Therapeutics, University of Porto, Porto, Portugal.
Background And Aims: Predicting the treatment outcomes of biological therapies is an unmet need in Crohn's Disease. In this study, we explored the potential of serum neutrophil-related biomarkers to predict infliximab therapeutic results and disease progression in Crohn's Disease patients, over a 2-year period, in a real-world setting.
Methods: The study included 100 asymptomatic Crohn's Disease patients in the IFX maintenance phase from the prospective, observational, multicenter DIRECT study.
JAMA Netw Open
December 2024
Solving Kids' Cancer UK, London, United Kingdom.
Importance: In poor-prognosis children's cancers, new therapies may carry fresh hope for patients and parents. However, there is an absolute requirement for any new therapy to be properly evaluated to fulfill scientific, regulatory, and reimbursement requirements. Randomized clinical trials (RCTs) are considered the gold standard, but no consensus exists on how and when they should be deployed to best meet the needs of all stakeholders.
View Article and Find Full Text PDFJ Am Coll Cardiol
November 2024
British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
Background: Current guidelines recommend a strategy of clinical surveillance (CS) for patients with asymptomatic severe aortic stenosis (AS) and a normal left ventricular ejection fraction.
Objectives: The aim of this study was to conduct a study-level meta-analysis of randomized controlled trials (RCTs) evaluating the effect of early aortic valve replacement (AVR) compared with CS in patients with asymptomatic severe AS.
Methods: Studies were quantitatively assessed in a meta-analysis using random-effects modeling.
Eur Urol
December 2024
Department of Cancer Medicine and INSERM U981, Université Paris-Sud, Université Paris-Saclay, Gustave Roussy, Villejuif, France.
JCO Oncol Pract
December 2024
Marie-Christine Etienne-Grimaldi, PhD, PharmD, Oncopharmacology Laboratory, Centre Antoine Lacassagne, Nice, France; Bernard Royer, PhD, PharmD, Laboratoire de Pharmacologie Clinique et Toxicologie, CHU Besançon and Univ. Franche-Comté, INSERM, EFS BFC, UMR1098, Besançon, France; Manon Launay, PhD, PharmD, Institut Curie, Service de Pharmacologie, Saint-Cloud, France; Antonin Schmitt, PhD, PharmD, Pharmacy Department, Centre Georges-François Leclerc, Dijon and INSERM U1231, University of Burgundy Franche-Comté, Dijon, France; Fabienne Thomas, PhD, PharmD, Oncopole Claudius Regaud, Institut Universitaire du Cancer and CRCT, University of Toulouse, Inserm, Toulouse, France; and Joseph Ciccolini, PhD, PharmD, COMPO Centre de Recherche en Cancérologie de Marseille Inserm U1068 and University Hospital of Marseille, Marseille, France.
PLoS Comput Biol
December 2024
National Centre for Biological Sciences, Tata Institute of Fundamental Research, Bangalore, India.
Biological signalling systems are complex, and efforts to build mechanistic models must confront a huge parameter space, indirect and sparse data, and frequently encounter multiscale and multiphysics phenomena. We present HOSS, a framework for Hierarchical Optimization of Systems Simulations, to address such problems. HOSS operates by breaking down extensive systems models into individual pathway blocks organized in a nested hierarchy.
View Article and Find Full Text PDFFood Chem Toxicol
November 2024
Université Paris Cité and Université Sorbonne Paris Nord, Inserm, INRAE, Centre for Research in Epidemiology and StatisticS (CRESS), Paris, France. Electronic address:
Exposure to environmental chemicals has been associated with higher risk of childhood allergies. This study aimed to examine the association between infant's dietary exposure to mixtures of chemicals and allergic and respiratory multimorbidity in childhood. Dietary exposures were assessed at 8 and 12 months in 724 and 745 children of the EDEN cohort.
View Article and Find Full Text PDFBMJ
November 2024
UMR 1219 Bordeaux Population Health, University of Bordeaux and INSERM, Bordeaux, France.
Lung Cancer
November 2024
Medical Oncology Department, Hospital Clinic de Barcelona, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain; Laboratory of Translational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain. Electronic address:
Introduction: LIPI has been strongly correlated with immunotherapy (IT) outcomes in advanced NSCLC. Limited data is available for upfront chemotherapy (CT) + IT combinations. We aimed to study its prognostic value in 1st-line CT +/- IT +/- antiangiogenics.
View Article and Find Full Text PDFOncologist
November 2024
Department of Supportive and Palliative Care, Institut Paoli-Camettes, Aix-Marseille Univ, CNRS, INSERM, Marseille, France.
Background: While the use of chemotherapy near the end of life (EOL) has been identified as a relevant criterion for assessing quality of cancer care and has been estimated as non-beneficial, a trend of aggressiveness in cancer care during the last period of life remains. Both patients' sociodemographic characteristics and physicians' practice setting are associated with this use. The role of patients' psychosocial characteristics has however been understudied.
View Article and Find Full Text PDFEur Heart J
November 2024
Department of Clinical Science and Education, Division of Cardiology, Karolinska Institutet, Södersjukhuset, Stockholm, Sweden.